Evaluation of the COBAS TaqMan 48 Real-Time PCR System for Quantitation of Hepatitis B Virus DNA

Rafael M. Gordillo, Juan Gutiérrez, and Manuel Casal*

Microbiology and Parasitology Department, Hospital Universitario Reina Sofia, Cordoba, Spain

Received 24 August 2004/Returned for modification 14 January 2005/Accepted 22 February 2005

The purpose of this study was to evaluate the usefulness of the new real-time PCR COBAS TaqMan 48 analyzer, comparing it to the existing COBAS AMPLICOR HBV MONITOR based on conventional PCR technology. The study used 104 samples from different patients. No differences were found in the sensitivity of the tests. There was an excellent correlation between the sample with a viral load within the dynamic range of the two tests (r = 0.938). The COBAS TaqMan test has a wider linear range, and this fact enables quantifying of the viral load without diluting the sample.

Hepatitis B virus (HBV) is a member of the family Hepadnaviridae that causes acute and chronic hepatitis (6). It is estimated that 2 billion people have been infected by HBV all over the world and more than 350 million people have persistent infection (11). The availability of molecular diagnostic test has improved the handling of the disease and monitoring of the response to treatment (12). The main purpose of measuring HBV DNA is to confirm the activity of infection and possible candidacy of patients for antiviral treatment.

One of the present tests for amplification of target is the AMPLICOR HBV MONITOR test (Roche Molecular Systems) which is based on the amplification of DNA targets by the use of HBV-specific primers. The quantitative PCR system used in the MONITOR test calculates the initial amount of DNA by measuring it at the end of the amplification reaction (2). The results thus obtained are subject to errors caused by a “plateau” effect that occurs because of accumulation of the substance, exhaustion of the enzyme, dilution of reagents, and other reasons. This effect produces a reduction in the rate of exponential accumulation of final product (5).

The quantitation of real-time PCR is based on the evaluation of the threshold cycle (Ct) when the amplification products are detected for the first time. The amplified product is detected sooner when the initial viral load is higher. Real-time PCR has a greater precision in quantitation because the Ct is defined as the number of fractional cycles in which the fluorescence emitted by the sample exceeds a preset threshold (assigned level of fluorescence) and the appearance of specific fluorescent signal is considered a critical threshold value (Ct). The Ct is defined as the number of fractional cycles in which the fluorescence emitted by the sample exceeds a preset threshold (assigned level of fluorescence) and marks the beginning of an exponential growth phase of this signal.

The plasma obtained was divided in two parts. The quantitation of HBV DNA was carried out in parallel by AMPLICOR and TaqMan analyzers.

The HBV DNA for COBAS TaqMan was isolated by a manual and generic preparation sample kit (High Pure System viral nucleic acid kit), based on the bonding of nucleic acid to glass fibers, in accordance with the manufacturer’s instructions. TaqMan technology uses the 5′-3′ nuclease activity of thermostable Z05 DNA polymerase. It uses double-marked fluorescent hybridization probes that bond specifically to the sample between primers. The probe contains a fluorescent marker (reporter) and another colorant that inhibits the reporter fluorescence (quencher). The degradation of the hybridization probe releases the reporter, causing an increase of fluorescence emission. The COBAS TaqMan test quantifies the amplicons during the exponential phase of amplification. The appearance of specific fluorescent signal is considered a critical threshold value (Ct). The Ct is defined as the number of fractional cycles in which the fluorescence emitted by the sample exceeds a preset threshold (assigned level of fluorescence) and marks the beginning of an exponential growth phase of this signal.

The aim of this study was to evaluate the validity of the COBAS TaqMan 48 real-time PCR analyser (Roche) for detection and quantitation of HBV DNA in plasma, comparing the results to those obtained with the same samples using COBAS AMPLICOR MONITOR (Roche) PCR analyzer. The study was carried out using 104 blood samples collected from individual patients. The extracted blood was introduced in BD VACUTAINER tubes with 1 ml of ACD anticoagulant.
FIG. 1. Correlation between viral loads detected by the two tests in group A samples (Passing-Bablok and Bland-Altman).
comparison was also made of the technical difficulty of both options. The High Pure System proved to be more laborious and requires equipment that is not normally found in a laboratory.

In amplification and detection, the first variable of interest was the time taken to process 24 samples. The results in this regard were favorable for the COBAS TaqMan test. Results can be obtained using AMPLICOR in 5 hours, whereas the average time taken with the TaqMan unit was 2.5 hours. Another point of interest is the difference between both assays regarding the sensitivity of the test and its dynamic range.

The correspondence between results was studied by dividing the 104 samples into the following groups: group A, patients with viral loads within the range of both tests (56 samples); group B, patients with viral loads below the detection limit of both tests (34 samples); group C, patients with viral loads outside the range of the AMPLICOR test (14 samples); Viral loads were converted into logarithms for easier handling. Passing-Bablok and Bland-Altman statistical tests were used to establish the agreement between both tests (1, 3) (Fig. 1). The resulting correlation coefficient was \( r = 0.938 \). In group B samples the viral load was undetectable with both assays, therefore there was complete correlation between AMPLICOR and TaqMan. In the group C samples an attempt was made to assess the importance of having a test with a wide dynamic range such as COBAS TaqMan. With the COBAS AMPLICOR MONITOR HBV analyzer there were 14 samples whose viral load was outside the range limits of technique (200 copies/ml to 200,000 copies/ml), 12 above the upper limit, and 2 below the lower limit. Using the COBAS TaqMan unit was possible to quantify the viral load within the limits of its dynamic range \((110,000,000 \text{ IU/ml} [660,000,000 \text{ copies/ml}] \text{ to } 30 \text{ IU/ml} [180 \text{ copies/ml}])\) in nine samples (64%). (Table 1).

<table>
<thead>
<tr>
<th>Place in relation to dynamic range</th>
<th>AMPLICOR</th>
<th>TaqMan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Above the range</td>
<td>47,700,000 (7.6785)</td>
<td>169,000,000 (8.2278)</td>
</tr>
<tr>
<td></td>
<td>455,000 (5.6580)</td>
<td>670,450 (5.8263)</td>
</tr>
<tr>
<td></td>
<td>2,040,000 (6.3096)</td>
<td>16,207,400 (7.2097)</td>
</tr>
<tr>
<td></td>
<td>2,730,000 (6.4361)</td>
<td>43,068,000 (7.6341)</td>
</tr>
<tr>
<td></td>
<td>6,690,000 (6.7551)</td>
<td>11,814,000 (7.0723)</td>
</tr>
<tr>
<td></td>
<td>27,800,000 (7.4440)</td>
<td>295,074,000 (8.4699)</td>
</tr>
<tr>
<td></td>
<td>4,080,000 (6.0106)</td>
<td>281,688,000 (8.4497)</td>
</tr>
<tr>
<td>Below the range</td>
<td>73 (1.8633)</td>
<td>52 (1.7160)</td>
</tr>
<tr>
<td></td>
<td>114 (2.0569)</td>
<td>273 (2.4361)</td>
</tr>
</tbody>
</table>

\(^a\) 5.82 copies/IU.

In conclusion, it can be said that the COBAS TaqMan 48 analyser provides faster results than AMPLICOR, both tests have excellent correlation in samples with viral load within the dynamic range of both assays (\( r = 0.938 \)) and the greater dynamic range of COBAS TaqMan test provides more exact results without diluting the sample, especially in patients with very high viral loads.

The results obtained in this and other studies do not invalidate the use of COBAS AMPLICOR in laboratories that do not have real-time technology available. The quantitation of HBV DNA offered by COBAS AMPLICOR is extremely important in the management of large numbers of patients for confirming the condition of active replication as well as for evaluating response to treatment. Its use would therefore be justified and its validity demonstrated as a first step in follow-up of these patients. However, the characteristics of the test in real time justify its use in patients whose evaluation or follow-up cannot be considered certain within a linear range narrower than the conventional test. The fact that the procedure for the extraction of DNA for the AMPLICOR test is less laborious could be an element in its favor for use in smaller laboratories with fewer technical staff. An automatic system for the extraction of HBV DNA will become available in the near future, and this will further simplify this process.

REFERENCES


